Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab

Background/Aims: To investigate the long-term effects of multiple intravitreal injections (IVTs) of ranibizumab (Lucentis) on intraocular pressure (IOP) in patients with neovascular age-related macular degeneration. Methods: In 320 eyes, IOP measurements were performed at baseline prior to injection...

Full description

Bibliographic Details
Main Authors: Menke, Marcel N., Salam, Adzura, Framme, Carsten, Wolf, Sebastian
Format: Article
Language:English
English
Published: S. Karger AG 2013
Subjects:
Online Access:http://irep.iium.edu.my/31705/6/31705_Long-Term%20intraocular%20pressure.pdf
http://irep.iium.edu.my/31705/7/31705_Long-Term%20intraocular%20pressure_SCOPUS.pdf
_version_ 1796878164210745344
author Menke, Marcel N.
Salam, Adzura
Framme, Carsten
Wolf, Sebastian
author_facet Menke, Marcel N.
Salam, Adzura
Framme, Carsten
Wolf, Sebastian
author_sort Menke, Marcel N.
collection IIUM
description Background/Aims: To investigate the long-term effects of multiple intravitreal injections (IVTs) of ranibizumab (Lucentis) on intraocular pressure (IOP) in patients with neovascular age-related macular degeneration. Methods: In 320 eyes, IOP measurements were performed at baseline prior to injection and compared with IOP measurements of the last visit. Correlations between mean IOP change and total number of IVTs, visual acuity or patient age were tested. Results: The mean IOP increase was 0.8 ± 3.1 mm Hg (p < 0.0001). Seven eyes showed final IOP values between 22 and 25 mm Hg. The mean follow-up was 22.7 ± 14.1 months. No further correlations between IOP change and number of IVTs, visual acuity or patient age have been found. Conclusions: This study demonstrated a statistically significant IOP increase in patients treated with repeated injections of ranibizumab. However, IOP increase required no glaucoma treatment during the study. Therefore, repeated injections with ranibizumab can be considered safe with regard to long-term IOP changes in patients without ocular hypertension or glaucoma. Copyright © 2013 S. Karger AG, Basel.
first_indexed 2024-03-05T23:17:39Z
format Article
id oai:generic.eprints.org:31705
institution International Islamic University Malaysia
language English
English
last_indexed 2024-03-05T23:17:39Z
publishDate 2013
publisher S. Karger AG
record_format dspace
spelling oai:generic.eprints.org:317052024-01-10T03:06:41Z http://irep.iium.edu.my/31705/ Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab Menke, Marcel N. Salam, Adzura Framme, Carsten Wolf, Sebastian RE Ophthalmology Background/Aims: To investigate the long-term effects of multiple intravitreal injections (IVTs) of ranibizumab (Lucentis) on intraocular pressure (IOP) in patients with neovascular age-related macular degeneration. Methods: In 320 eyes, IOP measurements were performed at baseline prior to injection and compared with IOP measurements of the last visit. Correlations between mean IOP change and total number of IVTs, visual acuity or patient age were tested. Results: The mean IOP increase was 0.8 ± 3.1 mm Hg (p < 0.0001). Seven eyes showed final IOP values between 22 and 25 mm Hg. The mean follow-up was 22.7 ± 14.1 months. No further correlations between IOP change and number of IVTs, visual acuity or patient age have been found. Conclusions: This study demonstrated a statistically significant IOP increase in patients treated with repeated injections of ranibizumab. However, IOP increase required no glaucoma treatment during the study. Therefore, repeated injections with ranibizumab can be considered safe with regard to long-term IOP changes in patients without ocular hypertension or glaucoma. Copyright © 2013 S. Karger AG, Basel. S. Karger AG 2013-04 Article PeerReviewed application/pdf en http://irep.iium.edu.my/31705/6/31705_Long-Term%20intraocular%20pressure.pdf application/pdf en http://irep.iium.edu.my/31705/7/31705_Long-Term%20intraocular%20pressure_SCOPUS.pdf Menke, Marcel N. and Salam, Adzura and Framme, Carsten and Wolf, Sebastian (2013) Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab. Ophthalmologica, 229 (3). pp. 168-172. ISSN 0030-3755 E-ISSN 1423-0267 http://dx.doi.org/10.1159/000346397 10.1159/000346397
spellingShingle RE Ophthalmology
Menke, Marcel N.
Salam, Adzura
Framme, Carsten
Wolf, Sebastian
Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
title Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
title_full Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
title_fullStr Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
title_full_unstemmed Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
title_short Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
title_sort long term intraocular pressure changes in patients with neovascular age related macular degeneration treated with ranibizumab
topic RE Ophthalmology
url http://irep.iium.edu.my/31705/6/31705_Long-Term%20intraocular%20pressure.pdf
http://irep.iium.edu.my/31705/7/31705_Long-Term%20intraocular%20pressure_SCOPUS.pdf
work_keys_str_mv AT menkemarceln longtermintraocularpressurechangesinpatientswithneovascularagerelatedmaculardegenerationtreatedwithranibizumab
AT salamadzura longtermintraocularpressurechangesinpatientswithneovascularagerelatedmaculardegenerationtreatedwithranibizumab
AT frammecarsten longtermintraocularpressurechangesinpatientswithneovascularagerelatedmaculardegenerationtreatedwithranibizumab
AT wolfsebastian longtermintraocularpressurechangesinpatientswithneovascularagerelatedmaculardegenerationtreatedwithranibizumab